Sikang Ruiqi (Shanghai) Pharmaceutical Co., Ltd

Sikang Ruiqi (Shanghai) Pharmaceutical Co., Ltd. (hereinafter referred to as "Sikang Ruiqi") was established on March 10, 2021, located in Zhangjiang Science City, Shanghai, with a building area of approximately 2500 square meters. It is an innovative pharmaceutical enterprise that focuses on the exploration and innovation of dual target drugs, including highly selective small molecule chemical drugs, highly selective antibody biopharmaceuticals, and new generation ADC drugs.

Sikang Ruiqi is committed to becoming an innovative pharmaceutical company with international competitiveness, potential for international cooperation, and market share, guided by internationalization and clinical value. We strive to become one of the biopharmaceuticals in China's biopharmaceutical industry that can successfully achieve internationalization in the early stages.

Its research and development pipeline mainly focuses on the fields of tumors, tumor immunity, and autoimmunity. In the short to medium term, it mainly focuses on clinically validated targets, and based on basic biomedical and structural biology, it creates highly selective small molecule chemical drugs and antibody biologics, aiming to improve selectivity, treatment window, drug resistance, and medication safety, and provide more efficient and safe treatment methods for clinical practice.

Visit website